Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft (ODPHOENIX2)
Second Line Treatment of Knee Osteochondral Lesion With Decellularized Treated Osteochondral Allograft. Phase IIa Trial
Sponsor: TBF Genie Tissulaire
Terminated
Low accrual rate
This PHASE1/PHASE2 trial investigates Cartilage Injury and is currently terminated or withdrawn. TBF Genie Tissulaire leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Terminated PHASE1_PHASE2
Status: Unknown Status → Terminated
-
Jan 2021 — Feb 2022 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TBF Genie Tissulaire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.